FIGO 2018分期在现代放疗时代宫颈癌中的肿瘤学结局
本研究回顾性分析2010-2018年接受根治性放化疗的216例非转移性宫颈癌患者,所有患者治疗前均行MRI和CT/PET,采用调强外照射和三维图像引导近距离放疗。中位随访44.3个月,5年总生存率76.8%、无病生存率68.5%、局部区域无病生存率82.6%。FIGO 2018分期较2009版对总生存区分更好,但远处复发仍是重要问题。
要点
- FIGO 2018分期较2009版对总生存区分更好
- 盆腔和腹主动脉旁淋巴结阳性者总生存逐步变差(p<0.001)
- 图像引导放疗下局部区域控制良好,但远处复发仍突出
核心结论
- 在现代图像引导放疗时代,FIGO 2018分期能更好反映宫颈癌患者预后,但远处复发仍是重要问题,提示IIIC期需新治疗策略。
研究设计与样本
- 单中心回顾性队列研究,纳入2010-2018年接受根治性放化疗的216例成人非转移性宫颈癌患者,所有患者治疗前均有MRI和CT/PET,治疗采用调强外照射和三维图像引导近距离放疗。
主要发现
- 中位随访44.3个月,5年总生存率、无病生存率和局部区域无病生存率分别为76.8%、68.5%和82.6%。
- FIGO 2018分期较2009版对总生存区分更好,盆腔和腹主动脉旁淋巴结阳性者总生存逐步变差(p<0.001)。
- 多因素分析中,体能状态(p=0.044)和FIGO 2018分期(III期p=0.016;IVA期p=0.010)是死亡预测因素;FIGO 2018分期(III期p=0.003;IVA期p=0.001)是任何复发的预测因素;MRI肿瘤直径(p≤0.001)和淋巴结转移(p=0.024)是局部区域复发的预测因素。
临床怎么用
- 采用FIGO 2018分期结合治疗前MRI和CT/PET进行精准分期,有助于更准确评估宫颈癌预后。
- 对IIIC期宫颈癌应关注远处复发风险,探索新的治疗策略。
局限性
- 单中心回顾性研究,样本量216例,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The recently published ASTRO cervical cancer guidelines recommend the use of modern radiotherapy. Imaging is now incorporated in the updated FIGO 2018 staging with a new stage IIIC. This study aims to evaluate the oncologic outcomes and predictors of survival using FIGO 2018 staging in a cohort of patients treated in an era of high-precision image-guided radiotherapy. METHODS: We performed a retrospective cohort study of 216 adult cervical cancer patients treated with definitive chemoradiotherapy between 2010 and 2018. Eligible patients had non-metastatic cervical cancer treated at a single academic institution. All patients had pre-treatment MRI and CT/PET. Treatment protocol consisted of external beam intensity-modulated radiotherapy and 3D image-guided brachytherapy. Kaplan-Meier curves were used for survival analysis. Multivariate cox proportional-hazards model was performed to identify potential prognostic factors. RESULTS: Median age at diagnosis was 50 and median BMI was 26.4 kg/m2. Median follow-up time was 44.3 months. Five-year overall survival (OS), disease-free survival and loco-regional disease-free survival rates were 76.8%, 68.5% and 82.6%, respectively. FIGO 2018 showed better OS discrimination compared to FIGO 2009 classification. OS was increasingly worse with positive pelvic and para-aortic nodes (p < 0.001). In a multivariate prediction model, performance status (p = 0.044) and FIGO 2018 classification (stage III p = 0.016; stage IVA p = 0.010) were predictors of mortality; FIGO 2018 classification (stage III p = 0.003; stage IVA p = 0.001) was a predictor of any recurrence; MRI tumor diameter (p ≤ 0.001) and nodal metastases (p = 0.024) were predictors of loco-regional recurrence. CONCLUSIONS: Integration of state-of-the-art imaging in cervical cancer staging and in radiotherapy planning leads to good loco-regional control rates, however distant recurrence remains an important issue. FIGO 2018 staging better reflects patient prognosis, highlighting the need for new treatment strategies for stage IIIC cervical cancer.
引用
- Brodeur MN, Dejean R, Beauchemin MC, et al. Oncologic outcomes in the era of modern radiation therapy using FIGO 2018 staging system for cervical cancer. Gynecol Oncol. 2021. PMID: 34059350. doi:10.1016/j.ygyno.2021.05.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。